This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Amory, J. K. Articles by Bremner, W. J. Search for Related Content PubMed PubMed Citation Articles by Amory, J. K. Articles by Bremner, W. J.

Oral Testosterone-Triglyceride Conjugate in Rabbits: Single-Dose Pharmacokinetics and Comparison With Oral Testosterone Undecanoate

G. K. E. SCRIBA

D. W. AMORY

From the ^* Population Center for Research in Reproduction and the Department of Medicine, University of Washington, Seattle, Washington; Department of Pharmaceutical Chemistry, University of Jena, Jena, Germany; and Institute of Applied Physiology and Medicine, Seattle, Washington.

Correspondence: Dr John K. Amory, Box 356429, University of Washington, 1959 NE Pacific St, Seattle, WA 98195 (e-mail: jamory{at}u.washington.edu).

Development of a safe and effective oral form of testosterone has been inhibited by the rapid hepatic metabolism of nonalkylated androgens. Since triglycerides are absorbed via lymphatics and bypass the liver, we hypothesized that a testosterone-triglyceride conjugate (TTC) might allow for safe and effective oral testosterone therapy. Therefore, we studied the single-dose pharmacokinetics of oral administration of TTC in rabbits. Female New Zealand rabbits were administered 2, 4, or 8 mg/kg of TTC in sesame oil by gastric lavage. Testosterone undecanoate (TU) by gastric lavage was used as a positive control. Blood was sampled from a catheter in the auricular artery at 0, 15, 30, 60, 90, 120, 180, 240, 360, 480, and 600 minutes after drug administration. Samples were assayed for testosterone by a fluoroimmunoassay. Mean serum testosterone, area under the curve (AUC), and terminal half-life were calculated. Oral TTC administration resulted in rapid and marked increases in serum testosterone. Oral TTC resulted in higher maximum serum testosterone concentrations than oral TU at 8 mg/kg (TTC: 28.6 ± 7.9 nmol/L vs TU: 11.9 ± 2.1 nmol/L; P < .001) and 4 mg/kg (TTC: 11.5 ± 4.2 nmol/L vs TU: 3.6 ± 1.0 nmol/L; P < .001). In addition, the AUC was 1.8 to 2.6 times greater for TTC than TU at both doses (P < .05). The terminal half-life for both TU and TTC was between 3 and 5 hours and was not significantly different. We conclude that oral TTC is rapidly absorbed from the rabbit intestine and results in elevated concentrations of serum testosterone. The absorption of TTC appears to be superior to that of TU; however, the in vivo persistence of the 2 compounds is similar. TTC may offer an alternative to the use of TU for oral testosterone therapy. Further testing of this compound is warranted.

     Key words: Hypogonadism, androgen, lymphatics